logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Genentech, Inc.


USPTO Granted Patents = 3,298

% Expired Patents = 21.3



Trademarks = 79

Forward Citations = 67,755

Loading Chart...
Loading Chart...

2,653 inventors (with patents filed for the assignee):

goldMedal William I Wood (643 out of 667 patents)

silverMedal Austin L Gurney (613 out of 719 patents)

bronzeMedal Audrey Goddard (602 out of 632 patents)

4.  Paul J Godowski (569 out of 594 patents)

5.  Victoria Smith (285 out of 312 patents)

6.  Colin K Watanabe (204 out of 213 patents)

7.  J Christopher Grimaldi (138 out of 145 patents)

8.  Leonard G Presta (121 out of 215 patents)

9.  Luc Roland Desnoyers (116 out of 143 patents)

10.  Yan Wu (103 out of 111 patents)

11.  Napoleone Ferrara (92 out of 106 patents)

12.  Mark S Dennis (87 out of 101 patents)

13.  Kevin P Baker (76 out of 92 patents)

14.  Henry Bernard Lowman (74 out of 95 patents)

15.  Avi J Ashkenazi (73 out of 78 patents)


Core Competencies:
NLRP3 Modulators
Bruton's Tyrosine Kinase
Tumor Treatment
Immunoconjugates
Deep Learning
Polypeptide Production
Cancer Biomarkers
Therapeutic Antibodies
Antibody Formulations
Combination Therapies
Protein Kinase Inhibitors
Image Processing

3,298 patents:

1. D1151997 - Medical syringe (2026-10-06),
2. D1151996 - Medical syringe (2026-10-06),
3. 12752005 - COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS (2026-10-06),
4. 12751951 - CDK inhibitors (2026-10-06),
5. 12749555 - Multipole moment based coarse grained representation of antibody electrostatics (2026-09-29),
6. 12749554 - Machine learning enabled prediction of molecular structures and properties (2026-09-29),
7. 12742192 - METHODS OF PROTEIN PRODUCTION (2026-09-22),
8. 12740984 - CDK inhibitors (2026-09-22),
9. 12740983 - CDK inhibitors (2026-09-22),
10. 12740962 - Methods of treating residual breast cancer with trastuzumab emtansine (2026-09-22),
11. 12738346 - Using neural networks to predict peptide immunogenicity (2026-09-15),
12. 12731251 - Multi arm machine learning models with attention for lesion segmentation (2026-09-08),
13. 12729459 - Randomized configuration targeted integration of nucleic acids (2026-09-08),
14. 12728162 - METHODS OF TREATING LUNG CANCER WITH A PD-1 AXIS BINDING ANTAGONIST, A PLATINUM AGENT, AND A TOPOISOMERASE II INHIBITOR (2026-09-08),
15. 12728129 - Macrocyclic broad spectrum antibiotics (2026-09-08),
Genentech, Inc., based in South San Francisco, CA, is a leader in biopharmaceutical innovations, focusing on the development of advanced therapies for serious medical conditions. The company specializes in areas such as NLRP3 modulators, Bruton's tyrosine kinase inhibitors, and immunoconjugates, contributing significantly to cancer treatment and therapeutic antibodies. Genentech also leverages deep learning and polypeptide production technologies to enhance drug discovery and development, positioning itself at the forefront of biotechnological advancements.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Genentech, Inc.
3,298 Patents

#1 in South San Francisco, CA

#34 in California

#135 in US

#280 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Genentech, Inc.

Forward Citations = 67,755

2,653 inventors:

goldMedal William I Wood (643 out of 667 patents)

silverMedal Austin L Gurney (613 out of 719 patents)

bronzeMedal Audrey Goddard (602 out of 632 patents)

4.  Paul J Godowski (569 out of 594 patents)

5.  Victoria Smith (285 out of 312 patents)

Please report any incorrect information to [email protected]
Loading…